Thrivent Financial for Lutherans’s BioXcel Therapeutics BTAI Stock Holding History

Thrivent Financial for Lutherans’s Portfolio BTAI Stock Details BTAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-2,500	Closed	-$51K	–	2519
2024 Q2	$51K	Hold	2,500	–	–	﹤0.01%	2512
2024 Q1	$113K	Hold	2,500	–	–	﹤0.01%	2488
2023 Q4	$118K	Buy	2,500 +1,250	+100%	+$69.5K	﹤0.01%	2460
2023 Q3	$50K	Buy	1,250 +625	+100%	+$63.2K	﹤0.01%	2420
2023 Q2	$64K	Buy	+625	New	+$208K	﹤0.01%	2443
2021 Q2	–	Sell	-1,294	Closed	-$893K	–	2462
2021 Q1	$893K	Sell	1,294 -167	-11%	-$134K	﹤0.01%	1946
2020 Q4	$1.08M	Buy	+1,461	New	+$1.14M	﹤0.01%	1701

Other funds holding BTAI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Thrivent Financial for Lutherans's BTAI Position: Q3 2024 in Review

Thrivent Financial for Lutherans sold out of BioXcel Therapeutics (BTAI) in Q3 2024, closing a stake of 2,500 shares — an estimated $51K sold.

Thrivent Financial for Lutherans first reported a position in BTAI in Q4 2020 and held it in 7 quarters. The position peaked at $1.08M in Q4 2020. 49 funds tracked by Wall St. Rank hold BTAI as of Q3 2024.

Thrivent Financial for Lutherans reported no remaining BioXcel Therapeutics position as of Q3 2024 after selling out during the quarter.
Thrivent Financial for Lutherans sold 2,500 BioXcel Therapeutics shares in Q3 2024, an estimated $51K.
Thrivent Financial for Lutherans first reported a position in BioXcel Therapeutics in Q4 2020 and held it in 7 quarters.
Thrivent Financial for Lutherans's BioXcel Therapeutics position peaked at $1.08M in Q4 2020.
49 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2024.

Based on Thrivent Financial for Lutherans's 13F filing for Q3 2024, filed 7 Nov 2024.